In this study, ACE (AGEprost®) treatment suppressed AR and SRC-1 expression in the prostate, followed by a decrease in PSA and PCNA expression, which are BPH and prostate proliferation biomarkers, respectively. Here, KLK3 is linked to benign prostatic hyperplasia.